ELR510444 Inhibits Tumor Growth and Angiogenesis by Abrogating HIF Activity and Disrupting Microtubules in Renal Cell Carcinoma
Jennifer S. Carew(University of Arizona), Steffan T. Nawrocki(University of Arizona), Marcel Mülbaier, Claudia M. Espitia(The University of Texas System), Joe Lewis(Affimed Therapeutics (Germany)), Juan Esquivel(The University of Texas at San Antonio Health Science Center), Francis J. Giles(National University of Ireland), Bernd Janssen, Christoph Schultes(University of London)
Cited by 22
Related Papers
Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab As Initial Therapy for Chronic Lymphocytic Leukemia
|Journal of Clinical Oncology|2005|951
Survivin: Key Regulator of Mitosis and Apoptosis and Novel Target for Cancer Therapeutics
|Clinical Cancer Research|2008|782